Table 2.
Outcomes at baseline and follow-up and change between baseline and 3-month follow-up.
| Baseline | Follow-up | Change | ||||
|---|---|---|---|---|---|---|
| n | Median (IQR) | n | Median (IQR) | n | Median (IQR) | |
| Molecular biomarkers | ||||||
| CRP (µg/mL) | 91 | 1.30 (0.56–2.95) | 86 | 1.35 (0.62–3.04) | 86 | −0.02 (−0.50 to 0.50) |
| ARGS-aggrecan (pmol/mL) | 91 | 0.15 (0.12–0.17) | 86 | 0.15 (0.12–0.17) | 86 | 0.01 (−0.02 to 0.02) |
| COMP (ng/mL) a | 91 | 800 (544–1051) | 85 | 798 (576–1095) | 85 | 11 (−109 to 134) |
| C2C (ng/mL) | 91 | 194 (153–239) | 86 | 214 (164–254) | 86 | 2 (−20 to 36) |
| HOOS/KOOS | ||||||
| Pain | 88 | 61.1 (41.7–75.0) | 87 | 66.7 (47.5–80.6) | 87 | 5.55 (−2.8 to 15.0) |
| Symptoms | 88 | 54.3 (35.7–67.9) | 88 | 53.6 (42.9–71.4) | 88 | 7.1 (−4.6 to 14.3) |
| ADL | 90 | 72.1 (52.6–86.8) | 88 | 76.7 (61.8–86.8) | 88 | 1.5 (−6.8 to 8.8) |
| Sport/Recreation | 87 | 30.0 (10.0–50.0) | 87 | 30.0 (10.0-55.0) | 84 | 0.0 (−11.9 to 10.0) |
| QoL | 90 | 43.8 (29.7–56.3) | 88 | 43.8 (31.3–61.5) | 88 | 0.0 (−6.3 to 12.5) |
| IPAQ-SF | ||||||
| MET-minutes/week | 81 | 2337 (1395–4626) | 78 | 2876 (1538–4334) | 70 | 588 (−817 to 1677) |
Abbreviations: ADL, activities of daily living; ARGS, neoepitope of aggrecan; C2C, collagen type II cleavage; COMP, cartilage oligomeric matrix protein; CRP, C-reactive protein; HOOS, Hip disability and Osteoarthritis Outcome Score; IPAQ-SF, International Physical Activity Questionnaire–Short Form; IQR, interquartile range (Q1-Q3); KOOS, Knee injury and Osteoarthritis Outcome Score; MET, metabolic equivalent of tasks; QoL, hip/knee-related quality of life.
a
n = 85 for COMP follow-up due to one value below the lower limit of detection.